BrainStorm Receives FDA Approval for Mesenchymal Stem Cell Trials for Multiple Sclerosis

BrainStorm Cell Therapeutics have received approval from the United States Food and Drug Administration to proceed with Phase 2 trials for their stem cell treatment for progressive multiple sclerosis (1). The treatment utilizes a proprietary autologous stem cell treatment, injecting patient-derived mesenchymal stem cells that secrete neurotrophic factors to stem the advance of disease (2). [Read More]

Get our newsletter for the latest news & updates.

Share the knowledge: